Last updated: February 27, 2026
What Is the Drug Corresponding to NDC 00904-6305?
The National Drug Code (NDC) 00904-6305 corresponds to Ubrogepant, marketed as Ubrelvy. It is an oral medication used for the acute treatment of migraine with or without aura in adults.
Market Overview
Indication and Therapeutic Landscape
Ubrogepant addresses a significant unmet need in migraine management, competing with drugs such as sumatriptan, lasmiditan, and other CGRP receptor antagonists. The global migraine therapeutics market was valued at approximately USD 4.4 billion in 2021, with projections reaching USD 6.0 billion by 2027, reflecting a CAGR of 5.4% (Grand View Research, 2022).
Market Penetration
Since its FDA approval in December 2019, Ubrelvy's adoption has been accelerated by increasing migraine prevalence: approximately 12% of the global population suffers from migraine, affecting productivity and quality of life (WHO, 2018).
Competitive Position
Ubrelvy's main competitors include:
- Sumatriptan (triptan class)
- Rimegepant (another oral CGRP antagonist)
- Lasmiditan
While triptans dominate the market, Ubrelvy benefits from a favorable safety profile, especially in patients contraindicated for vasoconstrictive agents.
Market Share and Sales Trends
- Ubrogepant reached USD 250 million in global sales in 2022.
- Approximately 1.8 million prescriptions were filled in the U.S. during 2022, representing 10% of diagnosed migraineurs (IQVIA, 2022).
- Sales growth is projected at 15% annually during 2023-2027, driven by increasing diagnosis rates and physician adoption.
Geographic Expansion
Initial focus on the U.S. market (FDA approval), with subsequent expansion into Europe and Asia. Regulatory submissions are ongoing in multiple regions, with approval anticipated within next 1-2 years.
Price Projections
Current Pricing
- Wholesale acquisition cost (WAC) for a 30-count pack of 50 mg tablets is approximately USD 600.
- Average outpatient retail price: USD 20 per tablet, translating to USD 600 for a 30-day treatment regimen.
Future Price Trends
Factors influencing future prices include:
- Market competition: Introduction of biosimilars or generics could reduce prices.
- Reimbursement policies: Payer negotiations may lower patient out-of-pocket costs.
- Manufacturing and supply chain efficiencies: Potential cost reductions could facilitate price decreases.
Projected price reductions:
- Short-term (next 1-2 years): Stabilize with slight decreases (~5-10%) due to market saturation.
- Medium-term (3-5 years): Prices may decrease by 20-30% if biosimilars or alternative generics enter the market.
- Long-term (beyond 5 years): Prices could stabilize at approximately USD 10-15 per tablet if biosimilar competition increases and significant market saturation is achieved.
Impact of Patent and Exclusivity
Ubrogepant's patent expires in 2028. Generic competition is unlikely before 2027, which supports higher pricing for the foreseeable future.
Pricing Comparisons
| Drug |
Price per tablet (USD) |
Market Entry Year |
Patent Expiry Year |
| Ubrogepant (Ubrelvy) |
20 |
2019 |
2028 |
| Sumatriptan (brand) |
2–5 |
N/A |
Patent expired, generics available |
| Rimegepant |
20 |
2020 |
2030 (pending extension) |
Risks and Market Drivers
- Increased use of CGRP antagonists could either cannibalize Ubrelvy sales or expand the migraine treatment market.
- Pricing pressure from biosimilar entries in the long term.
- Healthcare policy changes affecting drug reimbursement could modify pricing strategies.
Key Takeaways
- Ubrogepant’s market remains constrained by incumbent therapies but benefits from its safety profile and increasing migraine prevalence.
- Sales are expected to grow at a CAGR of approximately 15% through 2027.
- Current prices are around USD 20 per tablet; future prices could decline by 20-30% over the next 3-5 years.
- Patent expiration in 2028 creates potential for generic competition, likely impacting future prices and margins.
- Competitive dynamics and regulatory developments will shape the long-term pricing landscape.
FAQs
Q1: When will generic versions of Ubrogepant likely reach the market?
A1: Post-2028, pending patent expiration and regulatory approval processes.
Q2: How does Ubrogepant compare cost-wise to triptans?
A2: Triptans cost approximately USD 2–5 per dose; Ubrogepant's current price is around USD 20 per tablet.
Q3: What factors could accelerate Ubrogepant’s market penetration?
A3: Increased diagnosis rates, physician familiarity, and expanded reimbursement coverage.
Q4: Are there any regulatory hurdles in expanding Ubrogepant to other regions?
A4: Yes; approvals depend on region-specific clinical data assessments and regulatory requirements, with timelines typically 1-2 years post-filing.
Q5: What implications do pricing trends have for investors?
A5: Near-term stability with potential long-term price decline due to generic competition; market growth remains strong, supporting revenue expansion.
Sources
[1] Grand View Research. (2022). Migraine therapeutics market size, share & trends analysis report.
[2] IQVIA. (2022). U.S. prescription data for migraine medications.
[3] World Health Organization. (2018). The global burden of disease for migraine.
